Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving Average – Should You Sell?

Champions Oncology, Inc. (NASDAQ:CSBR) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.30 and traded as low as $6.17. Champions Oncology shares last traded at $6.23, with a volume of 3,932 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Champions Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Champions Oncology Trading Down 1.0%

The firm has a 50-day moving average price of $6.06 and a 200-day moving average price of $6.31. The company has a market capitalization of $84.45 million, a price-to-earnings ratio of -38.00 and a beta of 0.41.

Institutional Investors Weigh In On Champions Oncology

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Champions Oncology by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock valued at $2,158,000 after purchasing an additional 6,229 shares in the last quarter. Mink Brook Asset Management LLC bought a new stake in shares of Champions Oncology in the 4th quarter worth approximately $555,000. Acadian Asset Management LLC lifted its stake in Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 8,814 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Champions Oncology during the first quarter valued at approximately $201,000. Finally, Jane Street Group LLC bought a new stake in Champions Oncology during the first quarter worth approximately $200,000. 41.30% of the stock is owned by institutional investors and hedge funds.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.